R
Rutherford Health
Developing and building a network of oncology centres across the UK
About Rutherford Health
Rutherford Health PLC, originally founded as Proton Partners International in 2015 by Mike Moran and Karol Sikora, was a UK-based private oncology provider. The company aimed to develop a network of advanced cancer treatment centers across the United Kingdom and internationally, specializing in high-energy proton beam therapy, radiotherapy, chemotherapy, and diagnostic imaging.
The company established several Rutherford Cancer Centres in locations including South Wales, Northumberland, Liverpool, and the Thames Valley. These centers were equipped with technology from partners like Ion Beam Applications (IBA), Philips, and Elekta. The business model focused on treating both private and NHS patients. Rutherford Health also expanded into diagnostics, launching Rutherford Diagnostics and opening a community diagnostic center in partnership with Somerset NHS Foundation Trust. Further ventures included Rutherford Innovations and Rutherford Estates, as well as an international acquisition of the Gulf International Cancer Centre.
Despite significant investment, including over £240 million in capital expenditure to build its network, the company faced considerable financial challenges. A strategy described by a major shareholder as a "flawed expansion strategy" from 2015 to 2019 resulted in a high and unsustainable cash burn. The COVID-19 pandemic further exacerbated these issues by causing a critical reduction in the number of patients presenting at its centers. Efforts to secure sufficient contracts with the NHS to increase patient flow were unsuccessful. Faced with severe financial pressures and the inability to attract new funding, Rutherford Health went into liquidation in June 2022.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2020 | $25M | $101M | Undisclosed | — |
| GRANT✓Other financing | Jul 2016 | $594K | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Rutherford Health is 690 monthly website visits, up 245% over the last three months. Rutherford Health's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Rutherford Health in the Newport ecosystem
The Rutherford Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Arthurian Life Sciences
Series B and later1 investor entered at this stage
Shawbrook
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rutherford Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rutherford Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









